Trial Profile

An Open-label, Multinational, Multicenter, Single-arm Phase Ib/II Study to Evaluate Efficacy and Safety of Oral HH2853, a Selective EZH1/2 Inhibitor, in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HH 2853 (Primary)
Indications Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Haihe Biopharma

30 Jan 2026 Actual Primary Completion Date is 31 Oct 2025.
15 Sep 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Oct 2025.
11 Apr 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com